Aberdeen Fertility Centre, NHS Grampian Foresterhill, Aberdeen, AB25 2ZL, UK.
Fertility and Assisted Reproduction, Homerton University Hospital, Homerton Row, Hackney, E9 6SR, London.
Hum Reprod. 2017 Sep 1;32(9):1779-1785. doi: 10.1093/humrep/dex240.
Monitoring subclinical hypothyroidism (SCH) in women is believed to be important in terms of preventing overt hypothyroidism and optimizing the health and cognitive development of their children. Current systematic reviews have suggested an association between maternal SCH and adverse obstetric and neonatal outcomes. However, initiating the administration of thyroxine during pregnancy has failed to demonstrate appreciable health benefits. Hence there are calls by professional endocrine societies for optimizing serum thyroid-stimulating hormone (TSH) levels pre-conception. The strategy of ensuring that serum TSH levels are below 2.5 mIU/l during the pre-conception period has generated considerable uncertainty partly because the recommended level of <2.5 mIU/l is lower than those previously used to define the condition and partly due to uncertainty about the best screening programme clinicians can use in this context. Recalibrating the expected normal peri-conceptional range of serum TSH (<2.5 mIU/l), will have a significant impact on clinical services due to an inevitable increase in numbers of women diagnosed with SCH who will need to be investigated, treated and monitored. Serum TSH fulfils the criteria for a screening test and oral thyroxine is an inexpensive drug. Therefore, there is no reason to believe that screening cannot be undertaken in all women planning to conceive. Yet this approach will miss women whose pregnancies are unplanned and generate anxiety, further tests and many more prescriptions for thyroxine, coupled with the need for lifelong monitoring in affected women. A number of existing and ongoing randomized trials have evaluated the use of thyroxine in women with infertility or miscarriage with detectable thyroid auto-antibodies. These are unlikely to answer the question whether routine pre-conception testing for SCH in asymptomatic women is beneficial. Routine screening of women at risk of pregnancy and optimization of their thyroid status could result in significant health benefits for their offspring. Alternatively this approach could prove to be an expensive way of generating toxic knowledge resulting in anxiety, increased drug use and potential harm. Only large, appropriately designed studies can reveal the answer.
监测亚临床甲状腺功能减退症(SCH)对于预防显性甲状腺功能减退症以及优化女性及其子女的健康和认知发育非常重要。目前的系统评价表明,母亲的 SCH 与不良产科和新生儿结局之间存在关联。然而,在怀孕期间开始给予甲状腺素并没有显示出明显的健康益处。因此,专业内分泌学会呼吁在受孕前优化血清促甲状腺激素(TSH)水平。确保受孕前血清 TSH 水平低于 2.5mIU/L 的策略引起了相当大的不确定性,部分原因是推荐的<2.5mIU/L 水平低于以前用于定义该疾病的水平,部分原因是不确定临床医生在此背景下可以使用的最佳筛查方案。重新校准预期的正常受孕前血清 TSH(<2.5mIU/L)范围,由于诊断为 SCH 的女性数量不可避免地增加,需要进行调查、治疗和监测,这将对临床服务产生重大影响。血清 TSH 符合筛查试验的标准,口服甲状腺素是一种廉价药物。因此,没有理由认为不能在所有计划怀孕的女性中进行筛查。然而,这种方法会错过那些意外怀孕的女性,导致焦虑、进一步的检查和更多的甲状腺素处方,以及受影响女性需要终身监测。一些现有的和正在进行的随机试验已经评估了在可检测到甲状腺自身抗体的不孕或流产妇女中使用甲状腺素的情况。这些试验不太可能回答常规在无症状女性中进行 SCH 孕前检测是否有益的问题。对有妊娠风险的妇女进行常规筛查并优化其甲状腺功能状态,可能会为其子女带来显著的健康益处。或者,这种方法可能被证明是一种昂贵的产生毒性知识的方式,导致焦虑、增加药物使用和潜在危害。只有大型、设计合理的研究才能揭示答案。